Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report ) had its price target upped by Stifel Nicolaus from $39.00 to $40.00 in a report released on Thursday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. Stifel Nicolaus' target price would indicate a potential upside of 82.07% from the stock's previous close.
Get Syndax Pharmaceuticals alerts:
Sign Up
SNDX has been the subject of a number of other research reports. JPMorgan Chase & Co. raised their target price on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the company an "overweight" rating in a research note on Wednesday, March 20th. StockNews.com raised Syndax Pharmaceuticals to a "sell" rating in a research note on Friday, January 19th. Scotiabank lowered Syndax Pharmaceuticals from a "sector outperform" rating to a "sector perform" rating and lowered their price target for the stock from $36.00 to $23.00 in a research report on Wednesday, January 31st. Finally, HC Wainwright reissued a "buy" rating and set a $41.00 price objective on shares of Syndax Pharmaceuticals in a research report on Thursday. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $34.42.
Check Out Our Latest Report on SNDX
Syndax Pharmaceuticals Stock Performance NASDAQ:SNDX traded down $0.41 during trading hours on Thursday, reaching $21.97. The company's stock had a trading volume of 838,175 shares, compared to its average volume of 1,116,099. The firm has a 50-day simple moving average of $22.44 and a 200-day simple moving average of $20.17. Syndax Pharmaceuticals has a 1 year low of $11.22 and a 1 year high of $25.34. The firm has a market capitalization of $1.87 billion, a price-to-earnings ratio of -7.42 and a beta of 1.01.
Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report ) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, topping analysts' consensus estimates of ($0.96) by $0.11. During the same period in the previous year, the firm earned ($0.59) earnings per share. Equities analysts anticipate that Syndax Pharmaceuticals will post -3.74 earnings per share for the current fiscal year.
Institutional Trading of Syndax Pharmaceuticals A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SNDX. Assenagon Asset Management S.A. increased its stake in Syndax Pharmaceuticals by 47.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 390,538 shares of the company's stock worth $5,671,000 after buying an additional 125,893 shares during the period. Hudson Bay Capital Management LP increased its position in shares of Syndax Pharmaceuticals by 160.2% during the third quarter. Hudson Bay Capital Management LP now owns 1,236,186 shares of the company's stock worth $17,949,000 after acquiring an additional 761,186 shares during the period. Wellington Management Group LLP raised its stake in shares of Syndax Pharmaceuticals by 2.7% during the third quarter. Wellington Management Group LLP now owns 7,642,446 shares of the company's stock valued at $110,968,000 after acquiring an additional 198,262 shares in the last quarter. Qube Research & Technologies Ltd boosted its holdings in shares of Syndax Pharmaceuticals by 57.8% in the third quarter. Qube Research & Technologies Ltd now owns 206,394 shares of the company's stock valued at $2,997,000 after purchasing an additional 75,636 shares during the period. Finally, Jump Financial LLC grew its stake in Syndax Pharmaceuticals by 326.6% in the third quarter. Jump Financial LLC now owns 154,786 shares of the company's stock worth $2,247,000 after purchasing an additional 118,500 shares in the last quarter.
About Syndax Pharmaceuticals (
Get Free Report )
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
Featured Articles
Before you consider Syndax Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.
While Syndax Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
